Hematologic relapse remains the greatest obstacle to the cure of children with acute lymphoblastic leukemia (ALL). Recent studies have shown that patients with increased risk of relapse can be identified by measuring residual leukemic cells, called minimal residual disease (MRD), during clinical remission. Current PCR methods, however, for measuring MRD are cumbersome and time-consuming. To improve and simplify MRD assessment, we developed a real-time quantitative PCR (RQ-PCR) assay for detection of leukemic cells that harbor the TAL-1 deletion. We studied serial dilutions of leukemic DNA and found the assay had a sensitivity of detection of one leukemic cell among 100 000 normal cells. We then investigated 23 samples from eight children with ALL in clinical remission. We quantified residual leukemic cells by using the TAL-1 RQ-PCR assay and by using limiting dilution analysis. In 17 samples, both methods detected MRD levels у0.001%. The percentages of leukemic cells measured by the two methods correlated well (r 2 ‫؍‬ 0.926). In the remaining six samples, both methods detected fewer than 0.001% leukemic cells. We conclude the TAL-1 RQ-PCR assay can be used for rapid, sensitive and accurate assessment of MRD in T-lineage ALL with the TAL-1 deletion. Leukemia (2001) 15, 166-170. 
Introduction
With a cure rate of 80% in childhood acute lymphoblastic leukemia (ALL), great effort has been expended to precisely define risk assessment so that intensive treatment is given to children at high risk, whereas less toxic therapy is reserved for those with excellent prognosis. 1, 2 Several recent prospective studies have shown that the level of leukemic cells during clinical remission, known as minimal residual disease (MRD), is predictive of patient outcome. [3] [4] [5] The consensus from MRD studies is that clinical evaluation of MRD should improve the overall cure rate of ALL by identifying the patients with highest risk of relapse thereby allowing timely therapeutic intervention. 6, 7 The most common method for quantifying leukemic cells in ALL is polymerase chain reaction (PCR) amplification of leukemia-specific targets. 6, 8 Of the various PCR techniques, limiting dilution analysis [9] [10] [11] and comparative hybridization [12] [13] [14] have been used the most. However, these methods are cumbersome and time-consuming. Therefore, PCR-based methods must be simplified and improved before they can be routinely applied in the clinical setting. With that goal in mind, we investigated the ability of real-time quantitative PCR (RQ-PCR) to quantify leukemic cells harboring the TAL-1 deletion. 15 RQ-PCR permits accurate quantification by measuring PCR products during the exponential phase of the PCR reaction, 16 and reduces time and labor by eliminating post-PCR processing. The TAL-1 deletion is present in approximately 25% of cases of T-lineage ALL, but it is not found in normal T cells. 15, 17, 18 Therefore, the TAL-1 deletion provides a leukemia-specific target for MRD assessment in a significant number of patients with ALL. We developed a TaqMan RQ-PCR assay for detection and quantification of leukemic cells harboring the TAL-1 deletion. We applied this assay to analyze clinical samples from ALL patients. To assess the accuracy of our TAL-1 RQ-PCR assay, we compared RQ-PCR data with those obtained by limiting dilution analysis.
Materials and methods

Cells and cell culture
Bone marrow and peripheral blood samples were obtained from patients diagnosed with T-lineage ALL. Diagnostic DNA samples were tested by PCR amplification for SIL db1 -TAL   db1 and SIL db1 -TAL db2 deletions using the primers described. 
Quantification of leukemic cells by RQ-PCR
DNA samples were prepared by using the QIAamp blood kit (Qiagen, Valencia, CA, USA). To construct standard curves for quantification of leukemic cells with the TAL-1 deletion, DNA from the CEM-C7 cell line was diluted into DNA prepared from normal peripheral blood mononuclear cells (PBMC). Each DNA sample was analyzed in triplicate using an ABI Prism 7700 sequence detection system. PCR reactions contained 600 ng of DNA, 1 × TaqMan Universal Master Mix (Perkin Elmer, Foster City, CA, USA), 0.1 M of TAL-1 TaqMan probe, and 0.25 M TAL-1 TaqMan amplification primers ( Table 1 ) in a total volume of 50 l. The amplification conditions consisted of an initial incubation at 95°C for 10 min, then 50 cycles consisting of 15 s at 95°C and 60 s at 60°C. To control for the number of amplifiable genomes in the assay, we tested each sample in a parallel TaqMan assay to quantify the number of N-ras copies. PCR reactions contained 200 ng of DNA, 1 × TaqMan Universal Master Mix (Perkin Elmer, Foster City, CA, USA), 0.1 M of N-ras TaqMan probe, and 0.25 M N-ras TaqMan amplification primers (Table 1) in a total volume of 50 l. The amplification conditions consisted of an initial incubation at 95°C for 10 min, then 50 cycles consisting of 15 s at 95°C and 60 s at 60°C. An N-ras standard curve was constructed by making serial dilutions of normal PBMC DNA in water. The number of amplifiable genomes in each sample varied by less than two-fold (data not shown). Consequently, we did not adjust our TAL-1 TaqMan data.
Quantification of leukemic cells with TAL-1 deletion by limiting dilution analysis
A two-round PCR assay was used to detect a single copy of the TAL-1 deletion among 10 5 normal genomes. In the first round, 600 ng of genomic DNA was amplified for 25 cycles by using the SIL-db-5Ј primer and the TAL-db1-3Ј primer (Table 1) in a 50 l reaction. In the second round, the first round amplification mixture was diluted 1:100, and 1 l was amplified for 45 cycles by using the same amplification primers in a 25 l reaction. Amplification mixtures contained 1 The N-ras primers amplify an 80 bp product within exon 2 of the human N-ras gene. f Sequences of these oligonucleotides are from Pongers-Willemse et al. 19 Leukemia × PCR buffer (PE Applied Biosystems), 1.5 mm MgCl 2 , 200 M dNTPs, 0.25 m primers, and 1 unit of AmpliTaq Gold (PE Applied Biosystems). The amplification conditions consisted of an initial incubation at 95°C for 10 min, then cycling between 94°C for 20 s and 60°C for 40 s, followed by a final incubation at 72°C for 5 min. PCR products were analyzed by electrophoresis on a 3% agarose gel. MRD was quantified by limiting dilution analysis using 10 replicates and Poisson statistics. 20 The sensitivity of detection was 2 × 10 −6 for every sample tested.
Results
The TAL-1 deletion, present in approximately 25% of T-lineage cases of ALL, arises via site-specific recombination between the SIL and TAL-1 loci on chromosome 1p32. There are three breakpoints tightly clustered within the SIL locus and six breakpoints distributed within the TAL-1 locus. 21, 22 The two most frequently observed TAL-1 deletions involve the SIL db1 breakpoint rearranged to either the TAL db1 or the TAL db2 breakpoints ( Figure 1a) . In approximately 85% of cases, the SIL db1 breakpoint is rearranged with the TAL db1 breakpoint. 17, 18 Using sequence data from the SIL locus (accession Y07540) and the TAL-1 locus (accession S53698), we constructed amplification primers and a TaqMan probe for detection of the SIL db1 -TAL db1 deletion (Table 1, Figure 1b) . We synthesized the TaqMan probe complementary to sequences within the SIL locus so that a single probe could potentially be used with deletions arising from both major breakpoints within the TAL-1 locus. Further, the 5Ј-end of the probe was oriented toward the TAL-1 locus to minimize non-specific hydrolysis of the probe that might contribute to background fluorescence.
We tested the sensitivity of the TAL-1 RQ-PCR assay using the CEM-C7 cell line which contains the TAL-1 deletion. DNA from the CEM-C7 cells was diluted in normal PBMC DNA and analyzed by RQ-PCR. An excellent correlation was found between the input of leukemic cells and the fluorescence threshold (Ct) value (Figure 2) . In every experiment, with input DNA spanning five orders of magnitude, the correlation coefficient always exceeded 0.99. At a dilution of 10 −5 , there is Table 1 for details). During amplification (right panel) the TaqMan probe is hydrolyzed, resulting in increased fluorescence. an average of one genome per reaction. By using multiple replicates of the 10 −5 dilution, we found the RQ-PCR assay could detect a single leukemic genome.
We then used the TAL-1 RQ-PCR assay to investigate MRD in 23 bone marrow and peripheral blood samples from eight patients during clinical remission. To determine the accuracy of the TAL-1 RQ-PCR assay, we also investigated the same samples by using a limiting dilution assay for the TAL-1 deletion. Of the 23 samples, 17 samples had greater than 0.001% leukemic cells by both methods (Figure 3) . A good correlation (r 2 = 0.926) was found between the percentage of leukemic cells determined by both methods. In the remaining six samples, both methods detected fewer than 0.001% leukemic cells. Two samples had undetectable leukemic cells by both methods. In four samples, extremely low levels of MRD (0.0002-0.0009% leukemic cells) were detected by the limiting dilution method but not by the RQ-PCR assay. This apparent difference in sensitivity could arise from the greater mass of DNA being interrogated by the limiting dilution assay.
Discussion
We have developed a real-time PCR assay for detection and quantification of leukemic cells that contain the TAL-1 deletion. This assay, applicable to a significant number of ALL patients is rapid, sensitive, accurate, and less labor-intensive than current methods for MRD assessment. This assay will improve and simplify the assessment of MRD in patients with T-lineage ALL.
Recent studies have shown the predictive value of MRD assessment to identify ALL patients with increased risk of relapse. However, current PCR methods are not optimal for clinical evaluation of MRD. The most frequently used methods for MRD assessment are comparative hybridization and limiting dilution analysis. 6 Comparative hybridization is time-consuming, taking 2-3 days to complete. Further, data from these analyses are semi-quantitative. MRD levels are estimated by comparison with standards, and it is difficult to establish an endpoint of amplification in which each standard is still within the logarithmic phase. Limiting dilution analysis provides quantitative MRD estimates in the absence of standards. However, the overall process is laborious due to the multiple replicates analyzed, and the two rounds of PCR amplification performed. Both methods require post-PCR handling and analysis.
Competitive PCR is another method used to quantify molecular targets. Hosler and colleagues 23 recently reported the use of that approach to quantify leukemic cells with the TAL-1 deletion. The authors synthesized an internal calibration standard, a known quantity of which was added to PCR reactions. After amplification, the number of leukemic cells was calculated by comparing the intensity of the PCR products of the endogenous TAL-1 deletion and the calibrator. This assay was found to be precise and accurate, but analysis of multiple dilutions of the unknown samples was often needed to achieve the highest accuracy. 23 RQ-PCR using TaqMan technology affords significant advantages over current PCR methods. First, the TaqMan probe provides the sensitivity and specificity required for MRD assessment. The probe hybridizes to a known sequence between the amplification primers. It is cleaved, releasing fluorescence into the reaction, only when the primers direct amplification to that target sequence. Second, measurement of fluorescence in real time during the PCR reaction permits extrapolation of data back to the exponential phase of the amplification, thus avoiding problems associated with other comparative hybridization methods. Third, post-PCR processing of samples is eliminated, thereby reducing the overall time and labor of the assay.
We demonstrated that the TAL-1 RQ-PCR assay has a sensitivity of detection of one leukemic cell among 10 5 normal cells. This sensitivity is sufficient for discriminating ALL patients with high and low risk of hematologic relapse. Other recent reports have confirmed the potential of RQ-PCR to improve quantification of leukemic cells in ALL. [24] [25] [26] [27] Those reports, however, used antigen-receptor gene rearrangements for quantification of leukemic cells, a strategy that requires leukemic-specific assays for each patient. An additional way to simplify MRD assessment is to develop assays that are applicable to a group of patients. This strategy has been used to quantify MRD in patients with chronic myelogenous leukemia, 28, 29 acute myelogenous leukemia [30] [31] [32] acute promyelocytic leukemia 33 and lymphoma. 34, 35 In ALL, the TAL-1 deletion is present in approximately 5% of total patients and therefore our RQ-PCR assay will simplify the assessment of MRD in those cases.
We have developed an RQ-PCR assay for quantification of leukemic cells harboring the TAL-1 deletion. This standard assay, applicable to a significant number of patients with ALL, provides sensitive, accurate and timely assessment of MRD. Application of this assay in clinical studies will improve assessment of MRD in ALL, and should identify patients with increased risk of relapse.
